ExSight Ventures

DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics aimed at treating patients with rare and chronic diseases globally. The company utilizes innovative technology to enhance the delivery of RNA medicines to various tissues and organ systems, effectively addressing limitations faced by earlier platforms, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's therapies target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017, the company is headquartered in San Diego, California.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies aimed at protecting vision by targeting photoreceptors. Established in 2006, the company specializes in creating photoreceptor protective agents that address the FAS apoptotic pathway, which is critical for preserving photoreceptor cells. With a growing market for retinal drugs exceeding $7 billion, ONL Therapeutics aims to overcome the limitations of existing treatments that do not target the initial neural component of vision loss. The company’s drug programs include small-molecule peptides designed to protect photoreceptors during vision-threatening conditions such as retinal detachment, ultimately enhancing patient outcomes and supporting successful surgical interventions.

Re-Vana Therapeutics Ltd is a company based in Belfast, United Kingdom, specializing in ocular pharmaceuticals and drug delivery systems. Founded in 2016, it focuses on developing biodegradable drug delivery platforms to treat chronic eye diseases, including age-related macular degeneration, diabetic retinopathy, glaucoma, and uveitis. The company offers two main products: OcuLief, which provides long-term release of therapeutics for age-related macular degeneration and diabetic retinopathy, and EyeLief, designed for glaucoma and retinal diseases. These platforms utilize FDA-approved polymers, enabling the delivery of various therapeutic molecules over periods ranging from one week to a year. Re-Vana's approach aims to enhance patient compliance through reduced treatment frequency and pain, while also minimizing side effects and healthcare costs.

DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics aimed at treating patients with rare and chronic diseases globally. The company utilizes innovative technology to enhance the delivery of RNA medicines to various tissues and organ systems, effectively addressing limitations faced by earlier platforms, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's therapies target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017, the company is headquartered in San Diego, California.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies aimed at protecting vision by targeting photoreceptors. Established in 2006, the company specializes in creating photoreceptor protective agents that address the FAS apoptotic pathway, which is critical for preserving photoreceptor cells. With a growing market for retinal drugs exceeding $7 billion, ONL Therapeutics aims to overcome the limitations of existing treatments that do not target the initial neural component of vision loss. The company’s drug programs include small-molecule peptides designed to protect photoreceptors during vision-threatening conditions such as retinal detachment, ultimately enhancing patient outcomes and supporting successful surgical interventions.

LensGen, Inc. is an ophthalmic medical device company based in Irvine, California, that focuses on developing innovative solutions for presbyopia and cataracts. Founded in 2011, the company has created a biomimetic, curvature-changing intraocular lens designed to mimic the natural human lens. This lens, known as Juvene™, utilizes the eye's natural muscle contractions to adjust its shape and dioptric power on demand, allowing for clear and continuous vision at all distances. By restoring youthful vision, LensGen's technology eliminates the need for reading glasses, offering a significant advancement in the treatment of age-related vision issues.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.